| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
in Psoriatic Skin Is Regulated at a Posttranscriptional Level by MAPK-Activated Protein Kinase 21
* Department of Dermatology and
Department of Clinical Genetics, Aarhus University Hospital, Aarhus, Denmark;
Department of Biochemistry and Cell Biology and
Department of Biological Research, LEO Pharma, Ballerup, Denmark
Alterations in specific signal transduction pathways may explain the increased expression of proinflammatory cytokines seen in inflammatory diseases such as psoriasis. We reveal increased TNF-
protein expression, but similar TNF- mRNA levels, in lesional compared with nonlesional psoriatic skin, demonstrating for the first time that TNF- expression in lesional psoriatic skin is regulated posttranscriptionally. Increased levels of activated MAPK-activated protein kinase 2 (MK2) together with increased MK2 kinase activity were found in lesional compared with nonlesional psoriatic skin. Immunohistochemical analysis showed that activated MK2 was located in the basal layers of the psoriatic epidermis, whereas no positive staining was seen in nonlesional psoriatic skin. In vitro experiments demonstrated that both anisomycin and IL-1
caused a significant activation of p38 MAPK and MK2 in cultured normal human keratinocytes. In addition, TNF- protein levels were significantly up-regulated in keratinocytes stimulated with anisomycin or IL-1. This increase in TNF- protein expression was completely blocked by the p38 inhibitor, SB202190. Transfection of cultured keratinocytes with MK2-specific small interfering RNA led to a significant decrease in MK2 expression and a subsequent significant reduction in the protein expression of the proinflammatory cytokines TNF-, IL-6, and IL-8, whereas no change in the expression of the anti-inflammatory cytokine IL-10 was seen. This is the first time that MK2 expression and activity have been investigated in an inflammatory disease such as psoriasis. The results strongly suggest that increased activation of MK2 is responsible for the elevated and posttranscriptionally regulated TNF- protein expression in psoriatic skin, making MK2 a potential target in the treatment of psoriasis.
This article has been cited by other articles:
|
|
 |
|
  L. E. Kristensen, P. Geborek, and T. Saxne Dose escalation of infliximab therapy in arthritis patients is related to diagnosis and concomitant methotrexate treatment: observational results from the South Swedish Arthritis Treatment Group register Rheumatology, March 1, 2009; 48(3): 243 - 245. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. S. Stern Psoralen and Ultraviolet A Light Therapy for Psoriasis N. Engl. J. Med., August 16, 2007; 357(7): 682 - 690. [Full Text] [PDF]
|
|
|
|
 |
|
 A. White, C. A. Pargellis, J. M. Studts, B. G. Werneburg, and B. T. Farmer II Molecular basis of MAPK-activated protein kinase 2:p38 assembly PNAS, April 10, 2007; 104(15): 6353 - 6358. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Toichi, G. Torres, T. S. McCormick, T. Chang, M. A. Mascelli, C. L. Kauffman, N. Aria, A. B. Gottlieb, D. E. Everitt, B. Frederick, et al. An Anti-IL-12p40 Antibody Down-Regulates Type 1 Cytokines, Chemokines, and IL-12/IL-23 in Psoriasis J. Immunol., October 1, 2006; 177(7): 4917 - 4926. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
